Biomarin Historical Income Statement

BMRN Stock

USD 66.03 0.61 0.93%

Historical analysis of Biomarin Pharmaceutical income statement accounts such as Interest Expense of 18 M, Selling General Administrative of 246.1 M or Total Revenue of 2.5 B can show how well Biomarin Pharmaceutical performed in making a profits. Evaluating Biomarin Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Biomarin Pharmaceutical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Biomarin Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biomarin Pharmaceutical is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

About Biomarin Income Statement Analysis

Biomarin Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Biomarin Pharmaceutical shareholders. The income statement also shows Biomarin investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Biomarin Pharmaceutical Income Statement Chart

At this time, Biomarin Pharmaceutical's EBIT is very stable compared to the past year. As of the 1st of December 2024, Research Development is likely to grow to about 784.1 M, while Selling General Administrative is likely to drop about 246.1 M.

Selling General Administrative Gross Profit Other Operating Expenses Ebitda Non Recurring

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Biomarin Pharmaceutical minus its cost of goods sold. It is profit before Biomarin Pharmaceutical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Biomarin Pharmaceutical. It is also known as Biomarin Pharmaceutical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Biomarin Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's EBIT is very stable compared to the past year. As of the 1st of December 2024, Research Development is likely to grow to about 784.1 M, while Selling General Administrative is likely to drop about 246.1 M.

	2021	2022	2023	2024 (projected)
Gross Profit	1.4B	1.6B	1.8B	1.9B
Total Revenue	1.8B	2.1B	2.4B	2.5B

Gross Profit Total Revenue

Biomarin Pharmaceutical income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items	Selling And Marketing Expenses
Depreciation And Amortization		-0.21	0.25	0.8	0.78	0.75	0.59	0.62	0.5	0.77	0.84	0.71	0.65	0.28	0.67	-0.21	0.6	0.51	0.56	-0.23	0.05	0.79	0.9	0.42	0.54
Interest Expense	-0.21		0.71	0.21	0.25	0.33	-0.38	-0.44	0.6	-0.41	0.12	0.39	-0.4	-0.07	-0.17	-0.18	-0.25	0.6	0.38	-0.2	-0.4	-0.16	-0.1	-0.15	-0.21
Selling General Administrative	0.25	0.71		0.51	0.55	0.6	-0.21	-0.17	0.78	-0.07	0.4	0.66	-0.19	-0.04	-0.11	-0.04	-0.21	0.85	0.73	-0.06	-0.43	0.21	0.27	0.03	0.01
Total Revenue	0.8	0.21	0.51		1.0	0.99	0.35	0.62	0.87	0.72	0.98	0.98	0.39	0.01	0.45	-0.18	0.34	0.7	0.76	-0.22	-0.01	0.88	0.87	0.58	0.71
Gross Profit	0.78	0.25	0.55	1.0		0.99	0.33	0.6	0.89	0.7	0.97	0.98	0.37	0.0	0.4	-0.14	0.29	0.71	0.76	-0.18	-0.01	0.87	0.85	0.58	0.71
Other Operating Expenses	0.75	0.33	0.6	0.99	0.99		0.26	0.5	0.92	0.61	0.96	1.0	0.3	0.0	0.4	-0.22	0.29	0.76	0.78	-0.26	-0.1	0.81	0.84	0.5	0.62
Operating Income	0.59	-0.38	-0.21	0.35	0.33	0.26		0.61	0.02	0.66	0.38	0.22	0.99	0.79	0.59	0.24	0.58	0.03	-0.06	0.22	0.6	0.56	0.42	0.48	0.56
Ebit	0.62	-0.44	-0.17	0.62	0.6	0.5	0.61		0.21	0.98	0.64	0.45	0.65	0.02	0.38	0.17	0.37	0.06	0.3	0.14	0.42	0.83	0.59	0.72	0.9
Research Development	0.5	0.6	0.78	0.87	0.89	0.92	0.02	0.21		0.31	0.79	0.95	0.04	-0.08	0.15	-0.15	0.02	0.8	0.73	-0.19	-0.17	0.62	0.63	0.38	0.45
Ebitda	0.77	-0.41	-0.07	0.72	0.7	0.61	0.66	0.98	0.31		0.75	0.56	0.7	0.09	0.49	0.08	0.46	0.19	0.39	0.05	0.35	0.89	0.72	0.7	0.88
Cost Of Revenue	0.84	0.12	0.4	0.98	0.97	0.96	0.38	0.64	0.79	0.75		0.93	0.43	0.01	0.56	-0.3	0.47	0.66	0.73	-0.33	-0.01	0.88	0.91	0.57	0.69
Total Operating Expenses	0.71	0.39	0.66	0.98	0.98	1.0	0.22	0.45	0.95	0.56	0.93		0.26	-0.01	0.34	-0.18	0.22	0.78	0.78	-0.21	-0.1	0.79	0.8	0.49	0.6
Income Before Tax	0.65	-0.4	-0.19	0.39	0.37	0.3	0.99	0.65	0.04	0.7	0.43	0.26		0.76	0.65	0.16	0.65	0.07	0.0	0.15	0.54	0.59	0.48	0.45	0.57
Total Other Income Expense Net	0.28	-0.07	-0.04	0.01	0.0	0.0	0.79	0.02	-0.08	0.09	0.01	-0.01	0.76		0.42	0.21	0.42	0.06	-0.25	0.21	0.37	0.07	0.08	0.02	0.02
Net Income	0.67	-0.17	-0.11	0.45	0.4	0.4	0.59	0.38	0.15	0.49	0.56	0.34	0.65	0.42		-0.64	0.98	0.29	0.23	-0.65	0.15	0.44	0.59	0.24	0.29
Income Tax Expense	-0.21	-0.18	-0.04	-0.18	-0.14	-0.22	0.24	0.17	-0.15	0.08	-0.3	-0.18	0.16	0.21	-0.64		-0.63	-0.3	-0.29	1.0	0.35	0.02	-0.28	0.15	0.19
Net Income From Continuing Ops	0.6	-0.25	-0.21	0.34	0.29	0.29	0.58	0.37	0.02	0.46	0.47	0.22	0.65	0.42	0.98	-0.63		0.19	0.16	-0.63	0.15	0.38	0.52	0.19	0.24
Non Operating Income Net Other	0.51	0.6	0.85	0.7	0.71	0.76	0.03	0.06	0.8	0.19	0.66	0.78	0.07	0.06	0.29	-0.3	0.19		0.8	-0.32	-0.38	0.41	0.57	0.12	0.14
Non Recurring	0.56	0.38	0.73	0.76	0.76	0.78	-0.06	0.3	0.73	0.39	0.73	0.78	0.0	-0.25	0.23	-0.29	0.16	0.8		-0.32	-0.51	0.51	0.59	0.27	0.3
Tax Provision	-0.23	-0.2	-0.06	-0.22	-0.18	-0.26	0.22	0.14	-0.19	0.05	-0.33	-0.21	0.15	0.21	-0.65	1.0	-0.63	-0.32	-0.32		0.34	-0.01	-0.31	0.12	0.16
Interest Income	0.05	-0.4	-0.43	-0.01	-0.01	-0.1	0.6	0.42	-0.17	0.35	-0.01	-0.1	0.54	0.37	0.15	0.35	0.15	-0.38	-0.51	0.34		0.38	0.01	0.64	0.56
Net Interest Income	0.79	-0.16	0.21	0.88	0.87	0.81	0.56	0.83	0.62	0.89	0.88	0.79	0.59	0.07	0.44	0.02	0.38	0.41	0.51	-0.01	0.38		0.84	0.81	0.9
Reconciled Depreciation	0.9	-0.1	0.27	0.87	0.85	0.84	0.42	0.59	0.63	0.72	0.91	0.8	0.48	0.08	0.59	-0.28	0.52	0.57	0.59	-0.31	0.01	0.84		0.42	0.55
Extraordinary Items	0.42	-0.15	0.03	0.58	0.58	0.5	0.48	0.72	0.38	0.7	0.57	0.49	0.45	0.02	0.24	0.15	0.19	0.12	0.27	0.12	0.64	0.81	0.42		0.89
Selling And Marketing Expenses	0.54	-0.21	0.01	0.71	0.71	0.62	0.56	0.9	0.45	0.88	0.69	0.6	0.57	0.02	0.29	0.19	0.24	0.14	0.3	0.16	0.56	0.9	0.55	0.89

Click cells to compare fundamentals

Biomarin Pharmaceutical Account Relationship Matchups

Biomarin Pharmaceutical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	103.2M	105.9M	108.0M	102.0M	104.4M	109.6M
Interest Expense	23.5M	29.3M	15.3M	16.0M	17.3M	18.0M
Selling General Administrative	680.9M	334.3M	354.3M	403.7M	448.9M	246.1M
Total Revenue	1.7B	1.9B	1.8B	2.1B	2.4B	2.5B
Gross Profit	1.3B	1.3B	1.4B	1.6B	1.8B	1.9B
Other Operating Expenses	1.8B	2.0B	1.9B	2.1B	2.3B	2.4B
Operating Income	(125.5M)	(96.3M)	(60.0M)	57.5M	194.4M	204.2M
Ebit	(125.5M)	(111.7M)	(60.0M)	165.5M	205.9M	216.2M
Research Development	715.0M	628.1M	628.8M	649.6M	746.8M	784.1M
Ebitda	(22.2M)	(5.9M)	48.0M	267.5M	310.3M	325.8M
Cost Of Revenue	359.5M	524.3M	470.5M	483.7M	577.1M	605.9M
Total Operating Expenses	1.5B	1.4B	1.5B	1.6B	1.7B	1.8B
Income Before Tax	(94.8M)	(42.3M)	(75.4M)	149.6M	188.6M	198.0M
Total Other Income Expense Net	30.6M	(5.6M)	(15.3M)	14K	(5.9M)	(6.2M)
Net Income	(23.8M)	854.0M	(64.1M)	141.6M	167.6M	176.0M
Income Tax Expense	(71.0M)	(901.4M)	(11.3M)	8.0M	20.9M	22.0M
Net Income Applicable To Common Shares	(23.8M)	859.1M	(64.1M)	141.6M	162.8M	170.9M
Net Income From Continuing Ops	(23.8M)	859.1M	(64.1M)	141.6M	147.0M	154.4M
Non Operating Income Net Other	22.3M	22.2M	16.6M	10.5M	12.1M	7.1M
Tax Provision	(71.0M)	(901.4M)	(11.3M)	8.0M	4.7M	4.9M
Interest Income	22.7M	16.6M	10.5M	18.0M	49.0M	51.5M
Net Interest Income	(712K)	(12.7M)	(4.9M)	2.1M	34.1M	35.8M
Reconciled Depreciation	105.3M	105.2M	108.0M	102.0M	102.1M	111.0M

Pair Trading with Biomarin Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving against Biomarin Stock

0.87	BHC	Bausch Health Companies	Pair Corr
0.79	EWTX	Edgewise Therapeutics	Pair Corr
0.77	GILD	Gilead Sciences	Pair Corr
0.72	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.57	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr

The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.

The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:

How To Invest In Biomarin

Details

Is Biomarin Stock a good investment?

Details

What is Biomarin Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.607

Earnings Share

1.66

Revenue Per Share

14.529

Quarterly Revenue Growth

0.283

Return On Assets

0.03

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biomarin Historical Income Statement

About Biomarin Income Statement Analysis

Biomarin Pharmaceutical Income Statement Chart

Gross Profit

Other Operating Expenses

Biomarin Pharmaceutical income statement Correlations

Biomarin Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biomarin Pharmaceutical income statement Accounts

Pair Trading with Biomarin Pharmaceutical

Moving against Biomarin Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Tax Provision	+ 1.0	Income Tax Expense
Other Operating Expenses	+ 0.99	Total Revenue
Other Operating Expenses	+ 0.99	Gross Profit
Income Before Tax	+ 0.99	Operating Income

Tax Provision	- 0.65	Net Income
Income Tax Expense	- 0.64	Net Income
Tax Provision	- 0.63	Net Income From Continuing Ops
Net Income From Continuing Ops	- 0.63	Income Tax Expense
Interest Income	- 0.51	Non Recurring
Ebit	- 0.44	Interest Expense